复兴临床药理学，为阿尔茨海默病药物研发提供背景支持。
Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.
作者信息
Becker Robert E, Unni Latha K, Greig Nigel H
机构信息
Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
出版信息
Curr Alzheimer Res. 2009 Feb;6(1):79-81. doi: 10.2174/156720509787313916.
Abstract
Commercial priorities have been identified as negative factors in drug development. We trace the problem to inattention to sound clinical pharmacology practices. When properly applied, clinical pharmacology and associated drug development sciences can, hand in hand, facilitate success in commercial drug development.
摘要
商业利益已被视为药物研发中的负面因素。我们将问题追溯到对合理临床药理学实践的忽视。如果正确应用，临床药理学及相关药物研发科学能够携手促进商业药物研发的成功。
相似文献
1
Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.复兴临床药理学，为阿尔茨海默病药物研发提供背景支持。
Curr Alzheimer Res. 2009 Feb;6(1):79-81. doi: 10.2174/156720509787313916.
2
Preclinical pharmacology of metrifonate.
Pharmacotherapy. 1998 Mar-Apr;18(2 Pt 2):55-67; discussion 79-82.
3
The perils of Alzheimer's drug development.阿尔茨海默病药物研发的风险
Curr Alzheimer Res. 2009 Feb;6(1):77-8. doi: 10.2174/156720509787313871.
4
Metrifonate: update on a new antidementia agent.
J Clin Psychiatry. 1999 Nov;60(11):776-82.
5
Evaluating response to metrifonate.评估对敌百虫的反应。
J Clin Psychiatry. 1998;59 Suppl 9:33-7.
6
Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group.
Alzheimer Dis Assoc Disord. 2000 Jan-Mar;14(1):39-45. doi: 10.1097/00002093-200001000-00005.
7
Treatment of moderate to severe Alzheimer's disease: rationale and trial design.
Can J Neurol Sci. 2007 Mar;34 Suppl 1:S103-8. doi: 10.1017/s0317167100005667.
8
In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048.使用 HI-6、氯解磷定、苯扎氯铵和 K048 体外复能抑制的敌百虫的丁酰胆碱酯酶。
J Enzyme Inhib Med Chem. 2009 Jun;24(3):680-3. doi: 10.1080/14756360802328315.
9
Proceedings of the symposium on safety pharmacology, presented during the 3rd EPHAR meeting, Lyon, 6-9 July 2001. European Pharmacological Societies.
Fundam Clin Pharmacol. 2002 Apr;16(2):73-156.
10
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.用于治疗阿尔茨海默病的胆碱酯酶抑制剂：药理作用与临床疗效之间的关系。
Drugs Aging. 2004;21(7):453-78. doi: 10.2165/00002512-200421070-00004.
引用本文的文献
1
Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity.乙酰胆碱酯酶和丁酰胆碱酯酶抑制剂与免疫相遇。
Int J Mol Sci. 2014 Jun 2;15(6):9809-25. doi: 10.3390/ijms15069809.
2
A new regulatory road-map for Alzheimer's disease drug development.阿尔茨海默病药物研发的新监管路线图。
Curr Alzheimer Res. 2014 Mar;11(3):215-20. doi: 10.2174/156720501103140329210642.
3
Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?凤凰涅槃：阿尔茨海默病失败药物能否卷土重来？
Alzheimers Dement. 2013 Jan;9(1):50-7. doi: 10.1016/j.jalz.2012.01.007. Epub 2012 Mar 30.
4
Lost in translation: neuropsychiatric drug development.迷失在翻译中：神经精神药物研发。
Sci Transl Med. 2010 Dec 8;2(61):61rv6. doi: 10.1126/scitranslmed.3000446.
5
Why so few drugs for Alzheimer's disease? Are methods failing drugs?为什么治疗老年痴呆症的药物这么少？是方法让药物研发失败了吗？
Curr Alzheimer Res. 2010 Nov;7(7):642-51. doi: 10.2174/156720510793499075.
6
Advances in Alzheimer therapy: understanding pharmacological approaches to the disease.阿尔茨海默病治疗进展：了解针对该疾病的药理学方法。
Curr Alzheimer Res. 2009 Apr;6(2):83-5. doi: 10.2174/156720509787602924.
本文引用的文献
1
The perils of Alzheimer's drug development.阿尔茨海默病药物研发的风险
Curr Alzheimer Res. 2009 Feb;6(1):77-8. doi: 10.2174/156720509787313871.
2
Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?为什么这么多治疗阿尔茨海默病的药物在研发中失败？是时候采用新方法和新实践了吗？
J Alzheimers Dis. 2008 Oct;15(2):303-25. doi: 10.3233/jad-2008-15213.
3
Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.2008年及以后的阿尔茨海默病药物研发：问题与机遇
Curr Alzheimer Res. 2008 Aug;5(4):346-57. doi: 10.2174/156720508785132299.
4
Phenserine.苯丝氨酸
Expert Opin Investig Drugs. 2007 Jul;16(7):1087-97. doi: 10.1517/13543784.16.7.1087.
5
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.酒石酸苯丝氨酸概述，一种用于治疗阿尔茨海默病的新型乙酰胆碱酯酶抑制剂。
Curr Alzheimer Res. 2005 Jul;2(3):281-90. doi: 10.2174/1567205054367829.
6
The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate.用敌百虫治疗后阿尔茨海默病患者脑脊液乙酰胆碱酯酶活性的恢复情况。
Methods Find Exp Clin Pharmacol. 2000 Jan-Feb;22(1):57-61. doi: 10.1358/mf.2000.22.1.795849.
7
Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.敌百虫对阿尔茨海默病认知功能衰退的影响：一项双盲、安慰剂对照的6个月研究。
Alzheimer Dis Assoc Disord. 1998 Mar;12(1):54-7. doi: 10.1097/00002093-199803000-00009.
8
Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.乙酰胆碱酯酶抑制剂敌百虫治疗阿尔茨海默病的双盲、安慰剂对照研究。
Alzheimer Dis Assoc Disord. 1996 Fall;10(3):124-31. doi: 10.1097/00002093-199601030-00003.
9
Regulated and constitutive secretion of distinct molecular forms of acetylcholinesterase from PC12 cells.
J Cell Sci. 1993 Nov;106 ( Pt 3):731-40. doi: 10.1242/jcs.106.3.731.
10
Synthesis, transport and fate of acetylcholinesterase in cultured chick embryos muscle cells.培养的鸡胚肌肉细胞中乙酰胆碱酯酶的合成、运输及去向
Cell. 1980 Nov;22(2 Pt 2):583-94. doi: 10.1016/0092-8674(80)90368-2.
Zotero 插件